Recent approaches in vaccine development against streptococcus pneumoniae

Journal of Molecular Microbiology and Biotechnology

Volumn 24, Issue 4, 2014, Pages 215-227

  Tarahomjoo, Shirin ^a  

^a RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

Author keywords

Capsule; Cross reacting material 197; DNA vaccines; Pneumococcal conjugate vaccines; Proteins; Serotype coverage; Streptococcus pneumoniae; Vaccine delivery vehicles

Indexed keywords

BACTERIAL PROTEIN; DIPHTHERIA TOXOID CRM197; DNA VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; INACTIVATED VACCINE; SUBUNIT VACCINE; VACCINE;

DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; NONHUMAN; PNEUMOCOCCAL INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; ANIMAL; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PNEUMOCOCCAL INFECTIONS; TRENDS;

ANIMALS; DRUG DISCOVERY; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84908572291     PISSN: 14641801     EISSN: 16602412     Source Type: Journal    
DOI: 10.1159/000365052     Document Type: Review

References (92)

1. Adamou JE, Heinrichs JH, Erwin AL, et al: Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001; 69: 949-958.
2. Alexander JE, Lock RA, Peeters CCAM, et al: Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae . Infect Immun 1994; 62: 5683- 5688.
3. Aligholi M, Emaneini M, Jabalameli F, et al: Antibiotic susceptibility pattern of Gram-positive cocci cultured from patients in three university hospitals in Tehran, Iran during 2001- 2005. Acta Med Iran 2009; 47: 329-334.
4. Appelbaum PC: Resistance among Streptococcus pneumoniae : implications for drug selection. Clin Infect Dis 2002; 34: 1613-1620.
5. Arevalo MT, Xu Q, Paton SK, et al: Mucosal vaccination with a multi component adenovirus vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunol Med Microbiol 2009; 55: 346-351.
6. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW: Intranasal vaccination with pneumococcal surface protein A and interleukin- 12 augments antibody mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001; 69: 6718-6724.
7. Aspden TJ, Mason JD, Jones NS, Lowe J, Skaugrud O, Illum L: Chitosan as nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucocilliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509-513.
8. Audouy SAL, van Roosmalen ML, Neef J, et al: Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 2006; 24: 5434-5441.
9. Bentley SD, Anaensen DM, Mavroidi A, et al: Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet 2006; 2:e31.
10. Brady C, Killeen K, Taylor W, Patkar A: Carrier protein outsourcing. Bio proc Int 2012; 10: 50- 55.
11. Briles DE, Ades E, Paton JC, et al: Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae . Infect Immun 2000a;68: 796-800.
12. Briles DE, Hollingshead S, Brooks-Walter A, et al: The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000b;18: 1707-1711.
13. Brown JS, Ogunniyi AD, Woodrow MC, Holden DW, Paton JC: Immunization with components of two iron uptake ABC transporters protect mice against systemic Streptococcus pneumoniae infection. Infect Immun 2001; 69: 6702-6706.
14. Calix JJ, Nahm MH: A new pneumococcal serotype, 11E has a variably inactivated wcjE gene. J Infect Dis 2010; 202: 29-38.
15. Calix JJ, Porambo RJ, Brady AM, et al: Biochemical, genetic and serological characterization of two capsule subtypes among Streptococcus pneumoniae serotype 20 strains: discovery of a new pneumococcal serotypes. J Biol Chem 2012; 287: 27885-27894.
16. Campos IB, Darrieux M, Ferreira DM, et al: Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect 2008; 10: 481-488.
17. Cao J, Li D, Gong Y, et al: Casinolytic protease: a protein vaccine which could elicit serotype independent protection against invasive pneumococcal infection. Clin Exp Immunol 2009; 156: 52-60.
18. Carvalho SM, Kuipers OP, Neves AR: Environmental and nutritional factors that affect growth and metabolism of the pneumococcal serotype 2 strain D39 and its nonencapsulated derivative strain R6. PLoS One 2013; 8:e58492.
19. Cryz SJ, Furer E, Germanier R: Effect of chemical and heat inactivation on the anti genicity and immunogenicity of Vibrio cholerae . Infect Immun 1982; 38: 21-26.
20. Cui Y, Zhang X, Gong Y, et al: Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae . Vaccine 2011;29:1736- 1744.
21. Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, Hollingshead SK: The proline rich region of pneumococcal surface protein A and C contains surface accessible epitopes common to all pneumococci and elicits antibody mediated protection against sepsis. Infect Immun 2010; 78: 2163-2172.
22. Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes APY, Ren B, Briles DE, Hollingshead SK, Leite LCC: Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody mediated enhancement of complement deposition. Infect Immun 2007; 75: 5930-5938.
23. Douce G, Ross K, Cowan G, Ma J, Mitchell TJ: Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin from Streptococcus pneumoniae . Vaccine 2010; 28: 3231-3237.
24. Feldman MF, Wacker M, Hernandez M, et al: Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli . Proc Natl Acad Sci USA 2005; 102: 3016-3021.
25. Furuya Y, Regner M, Lobigas M, et al: Effect of inactivation method on cross protective immunity induced by whole killed influenza A viruses and commercial vaccine preparations. J Gen Virol 2010; 91: 1450-1460.
26. Giannini G, Rappuoli R, Ratti G: The amino acid sequence of two non toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 1984; 12: 4063-4069.
27. Giudice EL, Campbell JD: Needle free vaccine delivery. Adv Drug Deliv Rev 2006; 58: 68-89.
28. Goncalves VM, Zangirolami TC, Giordano RL, Raw I, Tanizaki MM, Giordano RC: Optimization of medium and cultivation conditions for capsular polysaccharide production by Strepococcus pneumoniae serotype 23F. Appl Microbiol Biotechnol 2002; 59: 713-717.
29. Gong Y, Wenchun X, Cui Y, et al: Immunization with a ZmpB based protein vaccine could protect against pneumococcal diseases in mice. Infect Immun 2011; 79: 867-878.
30. Green BA, Zhang Y, Masi AW, et al: PppA, a surface exposed protein of Streptococcus pneumoniae elicits cross reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 2005; 73: 981-989.
31. Hanniffy SB, Carter AT, Hitchin E, Wells JM: Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis 2007; 195: 185-193.
32. Harfouche C, Filippini S, Gianfaldoni C, et al: RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun 2012; 80: 451-460.
33. Hathaway LJ, Brugger SD, Morand B, et al: Capsule type of Streptococcus pneumoniae determines growth phenotype. PLoS Pathog 2012; 8:e1002574.
34. Hobson P, Barnfield C, Barnes A, Klavinskis LS: Mucosal immunization with DNA vaccines. Methods 2003; 31: 217-224.
35. Hvalbye BKR, Aaberge IS, Lovik M, Haneberg B: Intranasal immunization with heat inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun 1999; 67: 4320-4325.
36. Hyams C, Yuste J, Bax K, Camberlein E, Weiser JN, Brown JS: Streptococcus pneumoniae resistance to complement mediated immunity is dependent on the capsular serotype. Infect Immun 2010; 78: 716-725.
37. Jin P, Kong F, Xiao M, et al: First report of putative Streptococcus pneumonia e serotype 6D among nasopharyngeal isolates from Fijan children. J Infect Dis 2009; 200: 1375-1380.
38. Johnson HL, Deloria-Knoll M, Levine RS, et al: Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal global serotype project. PLoS Med 2010; 7:e1000348.
39. Johnson SE, Dykes JK, Jue DL, et al: Inhibition of pneumococcal carriage in mice by subcutaneous immunization with peptides from the common surface protein pneumococcal surface adhesin A. J Infect Dis 2002; 185: 489-496.
40. Kim E-H, Choi S-Y, Kwon M-K, et al: Streptococcus pneumoniae pep27 mutants as a live vaccine for serotype independent protection in mice. Vaccine 2012; 30: 2008-2019.
41. Kim S-N, Min K-K, Choi I-H, Kim S-W, Pyo S-N, Rhee D-K: Optimization of culture conditions for production of pneumococcal capsular polysaccharide type IV. Arch Pharm Res 1996; 19: 173-177.
42. Leal MM, Pereira DSG, Jessouroun E, Couto MAPG, Pereira N Jr: Investigation of cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae serotype 14. Electron J Biotechnol 2011; 14: 1.
43. Lewis DJ, Huo Z, Barnett S, et al: Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009; 4:e6999.
44. Lu Y-J, Leite L, Goncalves VM, et al: GMP grade pneumococcal whole cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010a;3: 7468-7475.
45. Lu Y-J, Yadav P, Clements JP, et al: Options for inactivation, adjuvant, and route of topical administration of a killed unencapsulated pneumococcal whole cell vaccine. Clin Vaccine Immunol 2010b;17: 1005-1012.
46. Malito E, Bursulaya B, Chen C, et al: Structural basis for lack of toxicity of the diphtheria toxin mutant CRM 197. Proc Natl Acad Sci USA 2012; 109: 5229-5234.
47. Malley R, Henneke P, Morse SC, et al: Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100: 1966-1971.
48. Malley R, Lisitch M, Stack A, et al: Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001; 69: 4870-4873.
49. Massaldi H, Ines Bessio M, Suarez N, Texeira E, Ross S, Ferreira F: Feature of bacterial growth and polysaccharide production of Streptococcus pneumoniae serotype 14. Bio technol Appl Bio chem 2010; 55: 37-43.
50. Matcalf BJ: Plasmid for production of CRM protein and diphtheria toxin. US Pat No 5614382. Washington, US Patent and Trademark Office, 1997.
51. McDaniel LS, McDaniel DO, Hollingshead SK, Briles D: Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 1998; 66: 4748-4754.
52. McDaniel LS, Sheffield JS, Delucchi P, Briles DE: PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 1991; 59: 222-228.
53. Medina M, Villeno J, Vintini E, Herbert EM, Raya R, Alvarez S: Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun 2008; 76: 2696-2705.
54. Melin M, Trzcinski K, Antonio M, et al: Serotype related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae . Infect Immun 2010; 78: 5252-5261.
55. Mera RM, Miller LA, Daniels JJ, Weil JG, White AR: Increasing prevalence of multidrug resistant Streptococcus pneumoniae in the US over a 10-year period: Alexander project. Diagn Microbiol Infect Dis 2005; 51: 195-200.
56. Miyaji EN, Dias WO, Tanizaki MM, Leite LCC: Protective efficacy of PspA-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 2003; 37: 53-57.
57. Miyaji EN, Ferreira DM, Lopes APY, Brandileone CC, Dias WO, Leite LCC: Analysis of serum cross reactivity and cross protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades. Infect Immun 2002; 70: 5086-5090.
58. Moffitt KL, Gierahn TM, Lu Y-J, et al: T H 17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 2011; 9: 158-165.
59. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D: Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011; 24: 557-591.
60. Morona JK, Morona R, Miller DC, Paton JC: Mutational analysis of the carboxy terminal (YGX) 4 repeat domain of CPSD, an auto phosphorylating tyrosine kinase required for capsule biosynthesis in Streptococcus pneumoniae . J Bacteriol 2003; 185: 3009-3019.
61. Muralinath M, Kuehn MJ, Roland KL, Curtiss R III: Immunization with Salmonella enteria serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae . Infect Immun 2011; 79: 887-894.
62. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH: Intranasal immunization with recombinant PspA fused with a flagellin enhances cross protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011; 29: 5731-5739.
63. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC: Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae . Infect Immun 2007; 75: 350-357.
64. Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC: Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001; 69: 5997-6003.
65. Oliveira MLS, Areas APM, Campos IB, et al: Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbe Infect 2006; 8: 1016-1024.
66. Oloo E, Yethan JA, Ochs MM, Carpick B, Oomen R: Structure guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease. J Biol Chem 2011; 286: 12133-12140.
67. Overweg K, Kerr A, Sluijter M, et al: The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun 2000; 68: 4180-4188.
68. Park IH, Pritchard DG, Cartee R, et al: Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae . J Clin Microbiol 2007; 45: 1225-1233.
69. Pouwels PH, Leer RJ, Shaw M, et al: Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol 1998; 41: 155-167.
70. Rappuoli R: Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens producing CRM 197. Appl Environ Microbiol 1983; 46: 560-564.
71. Roche AM, King SJ, Weiser JN: Live attenuated Streptococcus pneumoniae strains induce serotype independent mucosal and systemic protection in mice. Infect Immun 2007; 75: 2469-2475.
72. Roche H, Ren B, McDaniel LS, Hakansson A, Briles DE: Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae . Infect Immun 2003; 71: 4498-4505.
73. Romero-Steiner S, Pilshvili T, Sampson JS, et al: Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti- PsaA antibodies. Clin Diagn Lab Immunol 2003; 10: 246-251.
74. Rosch JW, Iverson AR, Humann J, et al: A live attenuated pneumococcal vaccine elicits CD4+ T cell dependent class switching and provides serotype independent protection against otitis media. EMBO Mol Med 2014; 6: 141-154.
75. Rosenow C, Ryan P, Weiser JN, et al: Contribution of novel choline binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae . Mol Microbiol 1997; 25: 819-829.
76. Sheng-De J, Kim Y-M, Kang H-K, Jung S-J, Kim D: Optimization of capsular polysaccharide production by Streptococcus pneumoniae type 3. J Micro biol Bio technol 2009; 19: 1374-1378.
77. Stefan A, Conti M, Rubboli D, Ravagli L, Presta E, Hockkoeppler A: Overexpression and purification of the recombinant diphtheria toxin variant CRM197 in Escherichia coli . J Bio technol 2011; 156: 245-252.
78. Talkington DF, Brown BG, Thrape JA, Koenig A, Russell H: Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 1996; 21: 17-22.
79. Terpe K: Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Micro biol Bio technol 2006; 72: 211-222.
80. Terra VS, Mills DC, Yates LE, Aboulhadid S, Cuccui J, Wren BW: Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J Med Microbiol 2012; 61: 919-926.
81. Vintini E, Villena J, Alvarez S, Medina M: Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis -PppA induces effective protection against pneumococcal infection in young mice. Clin Exp Immunol 2009; 159: 351-362.
82. Wells JM, Robinson K, Chamberlain LM, Schofield KM, Le Page RWF: Lactic acid bacteria as vaccine delivery vehicles. Antonie Van Leeuwenhoek 1996; 70: 317-330.
83. Whaley MJ, Sampson JS, Johnson SE, et al: Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine 2010; 28: 3071-3075.
84. WHO: Report of a WHO consultation on medicinal and other products in relation to human and animal transmissible spongiform encephalopathies. Geneva, WHO, 2003. http://www.who.int/biologicals/publications/en.
85. WHO: Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser 2005; 927: 66-86.
86. WHO: Target product profile (TPP) for the advanced market commitment (AMC) for pneumococcal conjugate vaccines. Geneva, WHO, 2008.
87. WHO: Pneumococcal vaccines, WHO position paper. Wkly Epidemiol Rec 2012; 87: 129-144.
88. Wizemann TM, Heinrichs JH, Adamou JE, et al: Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001; 69: 1593-1598.
89. Wu K, Zhang X, Shi J, et al: Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae infections in mice. Infect Immun 2010; 78: 1276-1283.
90. Xin W, Li Y, Mo H, Ronald KL, Curtiss R III: PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae . Infect Immun 2009; 77: 4518-4528.
91. Xu J, Dai W, Wang Z, Chen B, Li Z, Fan X: Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A protects mice against nasopharyngeal colonization by Streptococcus pneumoniae . Clin Vaccine Immunol 2011; 18: 75-81.
92. Yin J, Li G, Ren X, Herrler G: Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Bio technol 2007; 127: 335-347.